Kentucky · 2025 Regular Session · Bill
HB 788: AN ACT relating to buprenorphine products.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
HB 788 is a bill introduced in the Kentucky House on February 19, 2025. According to its official title, it concerns: AN ACT relating to buprenorphine products. Most recent recorded action (March 5, 2025): returned to Health Services (H).
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Create a new section of KRS Chapter 311 to require that a dosage regimen for Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone prescribed by a licensed physician to meet the treatment needs of a patient; require the Kentucky Board of Medical Licensure to promulgate administrative regulations to implement the requirement; create a new section of KRS Chapter 314 to require that a dosage regimen for Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone prescribed by a licensed advanced practice registered nurse meet the treatment needs of a patient; require the Kentucky Board of Nursing to promulgate administrative regulations to implement the requirement.
Sponsors
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| No sponsor recorded in source data. | ||||
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- returned to Health Services (H)
- 1st reading
- taken from Health Services (H)
- to Health Services (H)
- to Committee on Committees (H)
- introduced in House